Science is Often Flawed. It's Time we Embraced That.
By Julia Belluz and Steven Hoffman,
Vox
| 05. 13. 2015
Untitled Document
In his book Derailed, about his fall from academic grace, the Dutch psychologist Diederik Stapel explained his preferred method for manipulating scientific data in detail that would make any nerd's jaw drop:
"I preferred to do it at home, late in the evening... I made myself some tea, put my computer on the table, took my notes from my bag, and used my fountain pen to write down a neat list of research projects and effects I had to produce.... Subsequently I began to enter my own data, row for row, column for column...3, 4, 6, 7, 8, 4, 5, 3, 5, 6, 7, 8, 5, 4, 3, 3, 2. When I was finished, I would do the first analyses. Often, these would not immediately produce the right results. Back to the matrix and alter data. 4, 6, 7, 5, 4, 7, 8, 2, 4, 4, 6, 5, 6, 7, 8, 5, 4. Just as long until all analyses worked out as planned."
In 2011, when Stapel was suspended over research fraud allegations, he was a rising...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...